As FAK is overexpressed in a variety of tumours, a series of FAK inhibitors have been developed and used in clinical studies in recent years, including GSK2256098, Defactinib (VS-6063, PF-04554878), VS-6062 (PF 562271), VS-4718 (PND-1186), and IN10018 (BI 853520, Ifebemtinib) [479–481]. Here, PTK2 is linked to neoplasm.